What is FlowMetric?
Headquartered in Doylestown, Pennsylvania, FlowMetric operates as a comprehensive contract research organization (CRO) dedicated to the advancement of flow cytometry solutions. The company serves as a vital partner for global pharmaceutical entities, offering specialized expertise that spans the entire drug development lifecycle. From preclinical research and non-GLP studies to rigorous GLP toxicology assessments and complex Clinical Phase 0-IV trials, FlowMetric provides the analytical precision necessary for modern therapeutic validation. Their dual-presence through FlowMetric Europe further enhances their ability to deliver high-fidelity data and cell sorting services to a diverse, global client base, ensuring that precision medicine initiatives are supported by reliable, scalable, and compliant research infrastructure.
How much funding has FlowMetric raised?
FlowMetric has raised a total of $2.1M across 3 funding rounds:
Private Equity
$926K
Private Equity
$820K
Debt
$350K
Private Equity (2015): $926K, investors not publicly disclosed
Private Equity (2017): $820K, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Key Investors in FlowMetric
PPP
Public-Private Partnership
Undisclosed Private Equity
A private equity firm specializing in long-term capital deployment for high-growth contract research organizations within the healthcare and biotechnology sectors.
Undisclosed Private Equity
An institutional investor providing strategic backing to facilitate the expansion of specialized analytical service providers in the pharmaceutical development market.
What's next for FlowMetric?
With the recent influx of capital, FlowMetric is positioned to accelerate its service expansion and technological integration within the precision medicine ecosystem. The company is expected to leverage this financial backing to enhance its laboratory infrastructure and broaden its therapeutic reach, particularly in the high-growth areas of clinical trial support. As the demand for specialized flow cytometry services continues to rise, FlowMetric's strategic focus will likely remain on scaling its operational capacity to meet the stringent requirements of global pharmaceutical partners. By prioritizing innovation in cell analysis and maintaining its commitment to regulatory excellence, the firm is well-equipped to navigate the evolving complexities of the life sciences industry and sustain its long-term growth trajectory.
See full FlowMetric company page
